glp-1 news weight loss drugs leave users low on key nutrients, study finds CMS Extends Medicare's Short-Term Bridge

Andukuri R., Drincic A., and Rendell M., Alogliptin: A New Addition to the Class of DPP4 Inhibitors, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2 (2009): 117126

Evidence Rating Level : 2 (Good) Study Rundown : An important risk factor for colorectal cancer (CRC) is being overweight or obese

Step therapy (requiring you to try other treatments first) and prior authorizations are also common

This article examines the relationship between GLP-1 therapy and tiredness, explores contributing factors, and provides practical strategies to maintain energy levels while benefiting from treatment

Patients taking tirzepatide 10 mg achieved an average of 19.5% weight loss, and patients taking tirzepatide 15 mg achieved an average of 20.9% weight loss